Addyi is an FDA-approved medication designed to treat Hypoactive Sexual Desire Disorder (HSDD). It's owned by Sprout Pharmaceuticals and contains the active ingredient flibanserin. Addyi was first authorized for market use on August 18, 2015.
The generic version of Addyi will possibly be available after May 9, 2028. This date corresponds to the expiration of patent US7151103.
Addyi, with flibanserin as its active ingredient, is used to treat Hypoactive Sexual Desire Disorder (HSDD). The drug works by affecting the chemicals in the brain that are associated with sexual desire.
Addyi has a total of 4 patents. Three of these patents have already expired. The remaining patent (US7151103) titled 'Method of treating female hypoactive sexual desire disorder with flibanserin' is set to expire on May 9, 2028. Here are the details of the patent for the Addyi generic: